CVE-2017-17678

MEDIUMCVSS 6.1/10EPSS 0.84%

Last modified

CVE-2017-17678 is a medium-severity vulnerability rated 6.1/10 on the CVSS scale. BMC Remedy Mid Tier 9.1SP3 is affected by cross-site scripting (XSS). A DOM-based cross-site scripting vulnerability was discovered in a legacy utility.. EPSS estimates a 0.84% chance of exploitation in the next 30 days.

Description

BMC Remedy Mid Tier 9.1SP3 is affected by cross-site scripting (XSS). A DOM-based cross-site scripting vulnerability was discovered in a legacy utility.

Metrics

CVSS 3.1
6.1/10

CVSS:3.1/AV:N/AC:L/PR:N/UI:R/S:C/C:L/I:L/A:N

EPSS Probability
0.84%

53.3th percentile

Probability of exploitation in the next 30 days. Learn more

Weakness Enumeration

Affected Software

VendorProductVersionsUpdate
BmcRemedy Mid-Tier9.1Sp3

References

Timeline

Published
Last Modified
Status
Modified

Frequently Asked Questions

What is CVE-2017-17678?
BMC Remedy Mid Tier 9.1SP3 is affected by cross-site scripting (XSS). A DOM-based cross-site scripting vulnerability was discovered in a legacy utility.
How severe is CVE-2017-17678?
CVE-2017-17678 has a CVSS score of 6.1/10 (MEDIUM severity). The EPSS model estimates a 0.84% probability of exploitation in the next 30 days.
How do I fix CVE-2017-17678?
Check the vendor references and advisories linked above for patched versions and mitigation guidance. You can also run a Strix scan to test if your systems are affected.

Are you affected by CVE-2017-17678?

Run a free Strix scan to check your systems for this vulnerability.

Scan your code now

Source: NVD / NIST